Literature DB >> 29589317

Patient-Derived Xenograft Models of Colorectal Cancer: Procedures for Engraftment and Propagation.

Danielle M Burgenske1, David J Monsma1,2, Jeffrey P MacKeigan3,4.   

Abstract

Preclinical compounds tested in animal models often demonstrate limited efficacy when transitioned into patients. As a result, individuals are assigned to treatment regimens that may be ineffective at treating their disease. The development of more clinically relevant models, such as patient-derived xenografts (PDXs), will (1) more completely mimic the human condition and (2) more accurately predict tumor responses to previously untested therapeutics.PDX models are clinically relevant as tumor tissue is implanted directly from human donor to the mouse recipient. Therefore, these models prevent cell population selection, intentional or unintentional, as the human tissue adapts to an in vitro, two-dimensional environment prior to implantation into a three-dimensional in vivo murine host. Often, cell heterogeneity and tumor architecture can be maintained from human to the PDX model in the mouse. This protocol describes the engraftment and propagation processes for establishing colorectal (CRC) PDX models in mice, using tumor tissue from human subjects.

Entities:  

Keywords:  Colorectal cancer; Drug screening; Patient-derived xenograft; Preclinical in vivo efficacy; Tumor heterogeneity; Tumorgraft

Mesh:

Year:  2018        PMID: 29589317     DOI: 10.1007/978-1-4939-7765-9_20

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Establishment of a Novel PDX Mouse Model and Evaluation of the Tumor Suppression Efficacy of Bortezomib Against Liposarcoma.

Authors:  Eun Byeol Jo; Doopyo Hong; Young Sang Lee; Hyunjoo Lee; Jae Berm Park; Sung Joo Kim
Journal:  Transl Oncol       Date:  2018-11-14       Impact factor: 4.243

2.  Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model.

Authors:  Sumit Agarwal; Michael Behring; Hyung-Gyoon Kim; Prachi Bajpai; Balabhadrapatruni V S K Chakravarthi; Nirzari Gupta; Amr Elkholy; Sameer Al Diffalha; Sooryanarayana Varambally; Upender Manne
Journal:  Transl Oncol       Date:  2020-03-18       Impact factor: 4.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.